<p>Rallybio Corporation（納斯達克代碼：RLYB - 獲取免費報告）主要股東 Adar1 Capital Management, Llc 於 5 月 19 日（星期二）購買了 10,200 股該公司的股票。每股購買價格為 13.98 美元，總價值為 142,596.00 美元。收購後，該內部人士直接持有 926,352 股公司股票，估值約為 12,950,400.96 美元。此交易代表其持股比例增加了 1.11%。該交易已在向證券交易委員會的備案中披露，相關信息可通過此鏈接訪問。持有公司至少 10% 股份的主要股東需向 SEC 披露其交易。</p>
<p>Adar1 Capital Management, Llc 最近還進行了以下交易：</p>
<ul>
<li>5 月 18 日（星期一），Adar1 Capital Management, Llc 購買了 6,009 股 Rallybio 股票。每股購買成本為 13.98 美元，總交易額為 84,005.82 美元。</li>
<li>5 月 15 日（星期五），Adar1 Capital Management, Llc 購買了 300 股 Rallybio 股票。每股購買成本為 13.90 美元，總價值為 4,170.00 美元。</li>
<li>5 月 13 日（星期三），Adar1 Capital Management, Llc 購買了 79,259 股 Rallybio 股票。每股購買價格為 13.99 美元，總價值為 1,108,833.41 美元。</li>
<li>5 月 12 日（星期二），Adar1 Capital Management, Llc 購買了 800 股 Rallybio 股票。每股購買價格為 13.83 美元，總價值為 11,064.00 美元。</li>
<li>5 月 11 日（星期一），Adar1 Capital Management, Llc 收購了 50,000 股 Rallybio 股票。每股收購成本為 14.00 美元，總價值為 700,000.00 美元。</li>
<li>5 月 5 日（星期二），Adar1 Capital Management, Llc 收購了 35,101 股 Rallybio 股票。每股收購成本為 14.00 美元，總價值為 491,414.00 美元。</li>
<li>5 月 4 日（星期一），Adar1 Capital Management, Llc 購買了 120,804 股 Rallybio 股票。每股購買成本為 13.97 美元，總價值為 1,687,631.88 美元。</li>
</ul>
<h2>Rallybio 股票上漲 2.7%</h2>
<p>在週三的午盤交易中，RLYB 的股票上漲了 0.39 美元，達到 14.58 美元。該股票的交易量為 43,720 股，而其平均交易量為 642,666 股。Rallybio Corporation 的 12 個月最低價為 2.16 美元，最高價為 15.31 美元。該公司的 50 日簡單移動平均為 10.05 美元，200 日簡單移動平均為 7.25 美元。公司的市值為 7727 萬美元，市盈率為-3.20，貝塔值為-1.10。</p>
<p>Rallybio（納斯達克代碼：RLYB - 獲取免費報告）最近於 5 月 13 日（星期三）發佈了季度財報。公司報告每股收益為（1.46 美元），低於分析師一致預期的（1.20 美元），差額為（0.26 美元）。Rallybio 的淨利潤率為-911.07%，股本回報率為-55.79%。該公司在本季度的收入為 21 萬美元，而一致預期為 21 萬美元。</p>
<h2>分析師評級調整</h2>
<p>RLYB 最近成為幾份研究報告的主題。華爾街 Zen 在 3 月 28 日（星期六）的報告中將 Rallybio 的評級上調至 “持有”。Weiss Ratings 在 5 月 8 日（星期五）的研究報告中重申了對 Rallybio 股票的 “賣出（d-）” 評級。根據 MarketBeat 的數據，一位股票研究分析師對該股票給予了 “賣出” 評級，Rallybio 的平均評級為 “賣出”。</p>
<p><strong>查看我們最新的 RLYB 股票報告</strong></p>
<h2>機構投資者對 Rallybio 的看法</h2>
<p>一些機構投資者最近對該股票的持倉進行了調整。XTX Topco Ltd 在第四季度將其在 Rallybio 的持倉增加了 64.6%。XTX Topco Ltd 現在擁有 97,313 股公司股票，價值 67,000 美元，在此期間又購買了 38,205 股。Susquehanna International Group LLP 在第三季度將其在 Rallybio 的持倉增加了 485.9%。Susquehanna International Group LLP 現在擁有 136,294 股公司股票，價值 68,000 美元，在此期間又購買了 113,031 股。Geode Capital Management LLC 在第四季度將其在 Rallybio 的持倉增加了 1.2%。Geode Capital Management LLC 現在擁有 248,005 股公司股票，價值 170,000 美元，在此期間又購買了 2,996 股。Citadel Advisors LLC 在第三季度將其在 Rallybio 的持倉增加了 576.1%。Citadel Advisors LLC 現在擁有 438,705 股公司股票，價值 219,000 美元，在此期間又購買了 373,821 股。最後，Renaissance Technologies LLC 在第四季度將其在 Rallybio 的持倉增加了 16.9%。Renaissance Technologies LLC 現在擁有 835,692 股公司股票，價值 573,000 美元，在此期間又購買了 120,892 股。90.34% 的股票由機構投資者和對沖基金持有。</p>
<h2>關於 Rallybio</h2>
<p>（獲取免費報告）</p>
<p>Rallybio Therapeutics, Inc（納斯達克代碼：RLYB）是一家臨牀階段的生物技術公司，專注於開發和商業化針對罕見遺傳疾病患者的治療方案。該公司的科學方法利用多種模式，包括單克隆抗體、小分子和酶替代，以解決免疫缺陷、代謝紊亂和皮膚病等領域的高未滿足需求的疾病。Rallybio 的產品線旨在通過註冊臨牀試驗推進，目標是為目前缺乏或沒有批准治療方案的患者提供首創或最佳治療。</p>
<p>Rallybio 的主要項目之一是 RBX-100，一種針對先天性無胸腺症的研究性療法，這是一種罕見的兒童免疫缺陷病。</p>
<h2>另見</h2>
<ul>
<li>我們更看好的五隻股票比 Rallybio 更好</li>
<li>從 Zepbound 到 Foundayo：禮來最新業績支持口服 GLP-1 前景</li>
<li>人工智能整合開始：黑石與谷歌打造人工智能帝國</li>
<li>美國稀土公司在 2026 年第一季度表現強勁，鉅額 Serra Vera 交易即將達成</li>
<li>3 只太空基礎設施股票在 SpaceX IPO 前獲得動能</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkxZQg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkxZQg"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在 Rallybio 嗎？</h2>
<p>在你考慮 Rallybio 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前... 而 Rallybio 並不在名單上。</p>
<p>雖然 Rallybio 目前在分析師中被評為賣出評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

RLYB

紐交所高增長板生物技術指數 ETF - First Trust

生物科技 ETF - VanEck Vectors

<p>Adar1 Capital Management，Rallybio Corporation（NASDAQ:RLYB）的主要股東，購買了 10,200 股，每股價格為 13.98 美元，總計 142,596 美元。這次收購使他們的持股比例增加了 1.11%，使其總持股達到 926,352 股，估值約為 1295 萬美元。該交易已按照主要股東的要求向 SEC 披露。在午盤交易中，Rallybio 的股票上漲了 2.7%，達到 14.58 美元</p>

<p>Rallybio Corporation (NASDAQ:RLYB - Get Free Report) major shareholder Adar1 Capital Management, Llc bought 10,200 shares of the firm's stock in a transaction dated Tuesday, May 19th. The shares were purchased at an average price of $13.98 per share, with a total value of $142,596.00. Following the acquisition, the insider directly owned 926,352 shares in the company, valued at approximately $12,950,400.96. This trade represents a 1.11% increase in their position. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. Major shareholders that own at least 10% of a company's shares are required to disclose their transactions with the SEC.</p>
<div class="lb-trans"><p>Rallybio Corporation（納斯達克代碼：RLYB - 獲取免費報告）主要股東 Adar1 Capital Management, Llc 於 5 月 19 日（星期二）購買了 10,200 股該公司的股票。每股購買價格為 13.98 美元，總價值為 142,596.00 美元。收購後，該內部人士直接持有 926,352 股公司股票，估值約為 12,950,400.96 美元。此交易代表其持股比例增加了 1.11%。該交易已在向證券交易委員會的備案中披露，相關信息可通過此鏈接訪問。持有公司至少 10% 股份的主要股東需向 SEC 披露其交易。</p>
</div><p>Adar1 Capital Management, Llc also recently made the following trade(s):</p>
<div class="lb-trans"><p>Adar1 Capital Management, Llc 最近還進行了以下交易：</p>
</div><ul>
<li>On Monday, May 18th, Adar1 Capital Management, Llc purchased 6,009 shares of Rallybio stock. The shares were purchased at an average cost of $13.98 per share, for a total transaction of $84,005.82.</li>
<li>On Friday, May 15th, Adar1 Capital Management, Llc purchased 300 shares of Rallybio stock. The stock was acquired at an average cost of $13.90 per share, with a total value of $4,170.00.</li>
<li>On Wednesday, May 13th, Adar1 Capital Management, Llc purchased 79,259 shares of Rallybio stock. The stock was bought at an average price of $13.99 per share, with a total value of $1,108,833.41.</li>
<li>On Tuesday, May 12th, Adar1 Capital Management, Llc purchased 800 shares of Rallybio stock. The stock was bought at an average price of $13.83 per share, with a total value of $11,064.00.</li>
<li>On Monday, May 11th, Adar1 Capital Management, Llc acquired 50,000 shares of Rallybio stock. The stock was acquired at an average cost of $14.00 per share, with a total value of $700,000.00.</li>
<li>On Tuesday, May 5th, Adar1 Capital Management, Llc acquired 35,101 shares of Rallybio stock. The stock was acquired at an average cost of $14.00 per share, with a total value of $491,414.00.</li>
<li>On Monday, May 4th, Adar1 Capital Management, Llc purchased 120,804 shares of Rallybio stock. The shares were purchased at an average cost of $13.97 per share, with a total value of $1,687,631.88.</li>
</ul>
<div class="lb-trans"><ul>
<li>5 月 18 日（星期一），Adar1 Capital Management, Llc 購買了 6,009 股 Rallybio 股票。每股購買成本為 13.98 美元，總交易額為 84,005.82 美元。</li>
<li>5 月 15 日（星期五），Adar1 Capital Management, Llc 購買了 300 股 Rallybio 股票。每股購買成本為 13.90 美元，總價值為 4,170.00 美元。</li>
<li>5 月 13 日（星期三），Adar1 Capital Management, Llc 購買了 79,259 股 Rallybio 股票。每股購買價格為 13.99 美元，總價值為 1,108,833.41 美元。</li>
<li>5 月 12 日（星期二），Adar1 Capital Management, Llc 購買了 800 股 Rallybio 股票。每股購買價格為 13.83 美元，總價值為 11,064.00 美元。</li>
<li>5 月 11 日（星期一），Adar1 Capital Management, Llc 收購了 50,000 股 Rallybio 股票。每股收購成本為 14.00 美元，總價值為 700,000.00 美元。</li>
<li>5 月 5 日（星期二），Adar1 Capital Management, Llc 收購了 35,101 股 Rallybio 股票。每股收購成本為 14.00 美元，總價值為 491,414.00 美元。</li>
<li>5 月 4 日（星期一），Adar1 Capital Management, Llc 購買了 120,804 股 Rallybio 股票。每股購買成本為 13.97 美元，總價值為 1,687,631.88 美元。</li>
</ul>
</div><h2>Rallybio Stock Up 2.7%</h2>
<div class="lb-trans"><h2>Rallybio 股票上漲 2.7%</h2>
</div><p>Shares of RLYB traded up $0.39 during midday trading on Wednesday, reaching $14.58. 43,720 shares of the stock were exchanged, compared to its average volume of 642,666. Rallybio Corporation has a 12-month low of $2.16 and a 12-month high of $15.31. The firm has a 50 day simple moving average of $10.05 and a 200-day simple moving average of $7.25. The company has a market cap of $77.27 million, a price-to-earnings ratio of -3.20 and a beta of -1.10.</p>
<div class="lb-trans"><p>在週三的午盤交易中，RLYB 的股票上漲了 0.39 美元，達到 14.58 美元。該股票的交易量為 43,720 股，而其平均交易量為 642,666 股。Rallybio Corporation 的 12 個月最低價為 2.16 美元，最高價為 15.31 美元。該公司的 50 日簡單移動平均為 10.05 美元，200 日簡單移動平均為 7.25 美元。公司的市值為 7727 萬美元，市盈率為-3.20，貝塔值為-1.10。</p>
</div><p>Rallybio (NASDAQ:RLYB - Get Free Report) last issued its quarterly earnings data on Wednesday, May 13th. The company reported ($1.46) earnings per share for the quarter, missing analysts' consensus estimates of ($1.20) by ($0.26). Rallybio had a negative net margin of 911.07% and a negative return on equity of 55.79%. The company had revenue of $0.21 million during the quarter, compared to the consensus estimate of $0.21 million.</p>
<div class="lb-trans"><p>Rallybio（納斯達克代碼：RLYB - 獲取免費報告）最近於 5 月 13 日（星期三）發佈了季度財報。公司報告每股收益為（1.46 美元），低於分析師一致預期的（1.20 美元），差額為（0.26 美元）。Rallybio 的淨利潤率為-911.07%，股本回報率為-55.79%。該公司在本季度的收入為 21 萬美元，而一致預期為 21 萬美元。</p>
</div><h2>Analyst Upgrades and Downgrades</h2>
<div class="lb-trans"><h2>分析師評級調整</h2>
</div><p>RLYB has been the topic of several recent research reports. Wall Street Zen raised Rallybio to a &#34;hold&#34; rating in a report on Saturday, March 28th. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of Rallybio in a research report on Friday, May 8th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Rallybio has an average rating of &#34;Sell&#34;.</p>
<div class="lb-trans"><p>RLYB 最近成為幾份研究報告的主題。華爾街 Zen 在 3 月 28 日（星期六）的報告中將 Rallybio 的評級上調至 “持有”。Weiss Ratings 在 5 月 8 日（星期五）的研究報告中重申了對 Rallybio 股票的 “賣出（d-）” 評級。根據 MarketBeat 的數據，一位股票研究分析師對該股票給予了 “賣出” 評級，Rallybio 的平均評級為 “賣出”。</p>
</div><p><strong>View Our Latest Stock Report on RLYB</strong></p>
<div class="lb-trans"><p><strong>查看我們最新的 RLYB 股票報告</strong></p>
</div><h2>Institutional Investors Weigh In On Rallybio</h2>
<div class="lb-trans"><h2>機構投資者對 Rallybio 的看法</h2>
</div><p>A number of institutional investors have recently made changes to their positions in the stock. XTX Topco Ltd boosted its position in shares of Rallybio by 64.6% during the fourth quarter. XTX Topco Ltd now owns 97,313 shares of the company's stock worth $67,000 after buying an additional 38,205 shares during the period. Susquehanna International Group LLP boosted its position in shares of Rallybio by 485.9% during the third quarter. Susquehanna International Group LLP now owns 136,294 shares of the company's stock worth $68,000 after buying an additional 113,031 shares during the period. Geode Capital Management LLC boosted its position in shares of Rallybio by 1.2% during the fourth quarter. Geode Capital Management LLC now owns 248,005 shares of the company's stock worth $170,000 after buying an additional 2,996 shares during the period. Citadel Advisors LLC boosted its position in shares of Rallybio by 576.1% during the third quarter. Citadel Advisors LLC now owns 438,705 shares of the company's stock worth $219,000 after buying an additional 373,821 shares during the period. Finally, Renaissance Technologies LLC boosted its position in shares of Rallybio by 16.9% during the fourth quarter. Renaissance Technologies LLC now owns 835,692 shares of the company's stock worth $573,000 after buying an additional 120,892 shares during the period. 90.34% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>一些機構投資者最近對該股票的持倉進行了調整。XTX Topco Ltd 在第四季度將其在 Rallybio 的持倉增加了 64.6%。XTX Topco Ltd 現在擁有 97,313 股公司股票，價值 67,000 美元，在此期間又購買了 38,205 股。Susquehanna International Group LLP 在第三季度將其在 Rallybio 的持倉增加了 485.9%。Susquehanna International Group LLP 現在擁有 136,294 股公司股票，價值 68,000 美元，在此期間又購買了 113,031 股。Geode Capital Management LLC 在第四季度將其在 Rallybio 的持倉增加了 1.2%。Geode Capital Management LLC 現在擁有 248,005 股公司股票，價值 170,000 美元，在此期間又購買了 2,996 股。Citadel Advisors LLC 在第三季度將其在 Rallybio 的持倉增加了 576.1%。Citadel Advisors LLC 現在擁有 438,705 股公司股票，價值 219,000 美元，在此期間又購買了 373,821 股。最後，Renaissance Technologies LLC 在第四季度將其在 Rallybio 的持倉增加了 16.9%。Renaissance Technologies LLC 現在擁有 835,692 股公司股票，價值 573,000 美元，在此期間又購買了 120,892 股。90.34% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>About Rallybio</h2>
<div class="lb-trans"><h2>關於 Rallybio</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Rallybio Therapeutics, Inc NASDAQ: RLYB is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company's scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio's pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.</p>
<div class="lb-trans"><p>Rallybio Therapeutics, Inc（納斯達克代碼：RLYB）是一家臨牀階段的生物技術公司，專注於開發和商業化針對罕見遺傳疾病患者的治療方案。該公司的科學方法利用多種模式，包括單克隆抗體、小分子和酶替代，以解決免疫缺陷、代謝紊亂和皮膚病等領域的高未滿足需求的疾病。Rallybio 的產品線旨在通過註冊臨牀試驗推進，目標是為目前缺乏或沒有批准治療方案的患者提供首創或最佳治療。</p>
</div><p>Among Rallybio's lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.</p>
<div class="lb-trans"><p>Rallybio 的主要項目之一是 RBX-100，一種針對先天性無胸腺症的研究性療法，這是一種罕見的兒童免疫缺陷病。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另見</h2>
</div><ul>
<li>Five stocks we like better than Rallybio</li>
<li>From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook</li>
<li>AI Consolidation Begins: Blackstone &amp; Google Forge an AI Empire</li>
<li>USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms</li>
<li>3 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPO</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票比 Rallybio 更好</li>
<li>從 Zepbound 到 Foundayo：禮來最新業績支持口服 GLP-1 前景</li>
<li>人工智能整合開始：黑石與谷歌打造人工智能帝國</li>
<li>美國稀土公司在 2026 年第一季度表現強勁，鉅額 Serra Vera 交易即將達成</li>
<li>3 只太空基礎設施股票在 SpaceX IPO 前獲得動能</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkxZQg" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=RLYB"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Rallybio Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在 Rallybio 嗎？</h2>
</div><p>Before you consider Rallybio, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Rallybio 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rallybio wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前... 而 Rallybio 並不在名單上。</p>
</div><p>While Rallybio currently has a Sell rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Rallybio 目前在分析師中被評為賣出評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Insider Buying: Rallybio (NASDAQ:RLYB) Major Shareholder Buys 10,200 Shares of Stock

Market Beat

Rallybio

2 倍做多納斯達克生物技術 ETF - ProShares

醫療業 ETF - SPDR

動態生物技術與基因組 ETF - Invesco

醫藥突破 ETF - ALPS

標普全球醫療股指數 ETF - iShares

標普生物技術 ETF - SPDR

Invesco Nasdaq Biotechnology ETF

標普生物技術 3 倍做多 - Direxion

納斯達克生物科技指數 ETF - iShares Nasdaq

美國制藥 ETF - iShares

醫療業 ETF - Vanguard

基因改革 ETF - ARK

內部交易：Rallybio（納斯達克代碼：RLYB）的主要股東購買了 10,200 股股票